Last reviewed 2026-04-20 · How we verify

Chronic- PF-06480605 450 mg SC Q4W (chronic-pf-06480605-450-mg-sc-q4w)

At a glance

Approved indications

• Moderate to severe atopic dermatitis
• Moderate to severe plaque psoriasis
• Moderate to severe hidradenitis suppurativa
• Moderate to severe erythromelalgia
• Moderate to severe prurigo nodularis
• Moderate to severe intertrigo
• Moderate to severe vitiligo
• Moderate to severe alopecia areata
• Moderate to severe lichen simplex chronicus
• Moderate to severe pemphigus vulgaris
• Moderate to severe bullous pemphigoid
• Moderate to severe generalized pustular psoriasis
• Moderate to severe palmoplantar pustulosis
• Moderate to severe axillary hidradenitis suppurativa
• Moderate to severe anogenital pruritus
• Moderate to severe prurigo nodularis
• Moderate to severe lichen sclerosus
• Moderate to severe epidermolysis bullosa acquisita
• Moderate to severe mucous membrane pemphigoid
• Moderate to severe chronic spontaneous urticaria

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• P-glycoprotein inhibitors (e.g., cyclosporine, tacrolimus)
• P-glycoprotein inducers (e.g., rifampin, carbamazepine)
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine)
• CYP2C8 inhibitors (e.g., gemfibrozil)
• CYP2C8 inducers (e.g., rifampin, carbamazepine)
• CYP2C9 inhibitors (e.g., fluconazole)
• CYP2C9 inducers (e.g., rifampin, carbamazepine)
• CYP2C19 inhibitors (e.g., omeprazole)
• CYP2C19 inducers (e.g., rifampin, carbamazepine)
• CYP3A4 substrates (e.g., midazolam, simvastatin)

Key clinical trials

• A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Chronic- PF-06480605 450 mg SC Q4W CI brief — competitive landscape report
• Chronic- PF-06480605 450 mg SC Q4W updates RSS · CI watch RSS
• Pfizer portfolio CI